Seniors’ Access
Is at Risk

Build Back Better Undermines Patient Access

Generic and biosimilar medicines save patients and U.S. health care trillions of dollars. Congress is considering policies putting patient access to these affordable medicines at risk.

LEARN MORE

Seniors’ Access
Is at Risk

Build Back Better Undermines Patient Access

Generic and biosimilar medicines save patients and U.S. health care trillions of dollars. Congress is considering policies putting patient access to these affordable medicines at risk.

LEARN MORE

Take Action Against the Misguided Drug Pricing Proposals Being Considered by Congress

The drug price negotiation framework that Congress is considering in its budget reconciliation package exchanges the proven cost reduction of generic and biosimilar market-based competition for a short-term hope of savings through direct government price limits.

FDA data shows generics reduce costs by as much as 90% compared to the brand-name drug when 6 or more generics enter the market.

Enhance market competition so generic and biosimilar medicines can do an even better job of their decades-proven work reducing spending on expensive brand-name drugs. Without it, brand monopolies could last forever.

Take Action Against the Misguided Drug Pricing Proposals Being Considered by Congress

The drug price negotiation framework that Congress is considering in its budget reconciliation package exchanges the proven cost reduction of generic and biosimilar market-based competition for a short-term hope of savings through direct government price limits.

FDA data shows generics reduce costs by as much as 90% compared to the brand-name drug when 6 or more generics enter the market.

Enhance market competition so generic and biosimilar medicines can do an even better job of their decades-proven work reducing spending on expensive brand-name drugs. Without it, brand monopolies could last forever.

Send a Message
to Your Lawmakers

Real stories from real patients make a real difference.

SEND A MESSAGE NOW